by The US drug discovery market is experiencing significant growth driven by advances in artificial intelligence, genomics, precision medicine, and increasing investments in pharmaceutical research and development. The country remains a global leader in drug innovation, supported by a robust biotechnology ecosystem and growing demand for novel therapeutics.
US Drug Discovery Market Size and Forecast 2026 to 2035
The US drug discovery market size accounted for USD 26.24 billion in 2025 and is predicted to increase from USD 28.66 billion in 2026 to approximately USD 63.02 billion by 2035, expanding at a CAGR of 9.16% from 2026 to 2035. The market is witnessing substantial growth due to escalating prevalence of chronic conditions, a surging demand for targeted precision therapies, and the integration of AI in preclinical research. This is further supported by significant private and federal research and development investments and robust clinical pipelines across major therapeutic areas.
Market Highlights
- By drug type, the small molecule segment generated the biggest market share in 2025.
- By drug type, the large molecule segment is expanding at the fastest CAGR between 2026 and 2035.
- By end user, the pharmaceutical companies segment accounted for the largest market share in 2025.
- By end user, the contract research organizations segment is projected to grow at a solid CAGR between 2026 and 2035.
What is Driving the Growth of the U.S. Drug Discovery Market?
The U.S. drug discovery market encompasses technologies, platforms, and services used to identify, optimize, and develop new therapeutic compounds for treating various diseases. The market plays a critical role in pharmaceutical innovation and is supported by strong research infrastructure, substantial healthcare spending, and favorable regulatory frameworks.
Increasing prevalence of chronic diseases, cancer, neurological disorders, infectious diseases, and rare diseases has intensified the need for innovative treatment approaches. In response, pharmaceutical companies and biotechnology firms are expanding their research capabilities and investing heavily in next-generation drug discovery technologies.
Growing collaborations among academic institutions, contract research organizations (CROs), and technology providers are further accelerating the pace of therapeutic development across the United States.
How is Artificial Intelligence Transforming the U.S. Drug Discovery Market?
Artificial Intelligence (AI) is revolutionizing drug discovery by reducing development timelines and improving the efficiency of identifying promising drug candidates.
Machine learning algorithms analyze massive datasets containing genomic, proteomic, and clinical information to uncover new therapeutic targets. AI-powered platforms enable virtual screening of millions of compounds, predict toxicity profiles, and optimize molecular structures with greater accuracy.
Generative AI is increasingly being used to design novel molecules, while predictive analytics are enhancing clinical trial design and patient selection. These advancements are helping pharmaceutical companies reduce research costs and improve success rates. AI also supports automation in laboratories, accelerating experimentation and enabling researchers to focus on complex scientific challenges.
What are the Major Trends Shaping the U.S. Drug Discovery Market?
Rising Adoption of Precision Medicine
Precision medicine is transforming therapeutic development by enabling treatments tailored to individual genetic profiles. Advances in genomics and biomarker research are driving the development of targeted therapies.
Increasing Investment in Biotechnology
Biotechnology companies are receiving strong financial support from venture capital firms, government agencies, and pharmaceutical companies, fostering innovation across multiple therapeutic areas.
Growing Demand for Biologics and Cell Therapies
Biologics, gene therapies, and cell-based therapies are becoming increasingly important in addressing complex diseases and unmet medical needs.
Expansion of High-Throughput Screening Technologies
High-throughput screening platforms are improving the speed and efficiency of identifying drug candidates, enabling researchers to evaluate thousands of compounds simultaneously.
Rising Strategic Collaborations
Partnerships between pharmaceutical companies, artificial intelligence firms, academic institutions, and contract research organizations are accelerating innovation and reducing drug development risks.
Which Therapeutic Areas are Creating New Opportunities?
Several therapeutic areas are driving demand for advanced drug discovery solutions, including:
- Oncology
- Neurology
- Cardiovascular diseases
- Infectious diseases
- Rare diseases
- Immunology
- Metabolic disorders
- Respiratory diseases
The growing focus on precision medicine and personalized therapies is expected to generate new opportunities across these segments.
What Does the Future Hold for the U.S. Drug Discovery Market?
The future of the U.S. drug discovery market will be shaped by advances in artificial intelligence, machine learning, quantum computing, genomics, and digital biology.
Emerging technologies are expected to accelerate drug development, improve success rates, and enable more personalized treatment approaches. The integration of AI with omics technologies and real-world data analytics will further transform the pharmaceutical research landscape. Growing investments in gene editing, RNA therapeutics, and precision medicine are likely to create substantial opportunities over the next decade.
Why is the U.S. Drug Discovery Market Expected to Witness Strong Growth?
The U.S. remains the world’s leading hub for pharmaceutical innovation due to its advanced research infrastructure, strong biotechnology ecosystem, and substantial investments in healthcare and life sciences.
As artificial intelligence, genomics, and precision medicine continue to redefine drug development, the U.S. drug discovery market is expected to experience sustained growth, creating new opportunities for pharmaceutical companies, biotechnology firms, research institutions, and healthcare providers.
The convergence of computational biology, AI-driven analytics, and advanced therapeutic modalities will continue to shape the next generation of medicines and revolutionize healthcare worldwide.
Who are the Leading Companies in the U.S. Drug Discovery Market?
Several global and domestic companies are shaping the competitive landscape through continuous innovation and strategic collaborations, including:
- Pfizer Inc.
- Merck & Co., Inc.
- Johnson & Johnson
- Bristol Myers Squibb
- Eli Lilly and Company
- Amgen Inc.
- Gilead Sciences, Inc.
- AbbVie Inc.
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc
These companies are investing heavily in AI-driven platforms, genomics, cell therapies, and computational biology to strengthen their market positions.
Get Free Sample : https://www.precedenceresearch.com/sample/8462
Recent Developments US Drug Discovery Market (2025-2026)
- In April 2026, AWS launched Amazon Bio Discovery, an AI-powered application that assists scientists in designing and testing novel drugs. This platform provides access to biological foundation models to generate and evaluate drug candidates while streamlining communication through a Health AI interface for virtual care, thereby enhancing the drug discovery process.
- In March 2026, Insilico Medicine launched PandaClaw, an autonomous AI agent within the PandaOmics platform that allows biologists to conduct complex multi-omics analyses using simple natural language. This tool eliminates the need for specialized computational experts, autonomously formulates workflows, cross-references expansive databases, and generates actionable disease hypotheses in real time.
